Literature DB >> 29880536

Pregabalin: what the patent litigation means for doctors and drug companies.

Darren Smyth1, Richard Croker2, Ben Goldacre3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29880536     DOI： 10.1136/bmj.k2318

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

1.  Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis.

Authors:  Stephen Robert Chapman; Mohammed Ibrahim Aladul; Raymond William Fitzpatrick
Journal:  BMJ Open       Date:  2019-08-01       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.